Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.82 |
| ▸ | JAK1 | P23458 | 3/20 | 0.65 |
| ▸ | JAK3 | P52333 | 3/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8230376 | 1.00 | PDE4B (0.82) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL4336100 | 1.00 | PDE4B (0.82) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL8222521 | 1.00 | PDE4B (0.82) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL4336092 | 1.00 | PDE4B (0.82) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL4929537 | 1.00 | PDE4B (0.82) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL583169 | 0.90 | PDE4B (1.00) | PDE4BPDE5AADORA1POLBMEN1 | |
| SCHEMBL583691 | 0.89 | PDE4B (1.00) | PDE4BPDE5AADORA1POLBMEN1 | |
| SCHEMBL12812014 | 0.89 | PDE4B (0.64) | PDE4BJAK1JAK3PDE5AADORA1 | |
| SCHEMBL583694 | 0.88 | PDE4B (0.85) | PDE4BPDE5AADORA1POLBMEN1 | |
| SCHEMBL14115808 | 0.88 | PDE4B (0.63) | PDE4BJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | claimed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885JAK1 622/4885JAK3 331/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885JAK1 2063/4885JAK3 1678/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | PDE4B 4/4885JAK1 933/4885JAK3 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.